Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model

類似資料

• AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice
  著者:: Crudele, Julie M., 等
  出版事項: (2015)
• The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy
  著者:: Finn, Jonathan D., 等
  出版事項: (2012)
• Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy
  著者:: Niemeyer, Glenn P., 等
  出版事項: (2009)
• An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
  著者:: Sun, Junjiang, 等
  出版事項: (2018)
• Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants
  著者:: Samelson-Jones, Benjamin J., 等
  出版事項: (2021)